Aldosterone as an independent factor in cerebrovascular damage

Clinical and Experimental Hypertension

Volumn 30, Issue 8, 2008, Pages 785-797

  Mulatero, Paolo ^a   Caserta, Mimma ^a   Bertello, Chiara ^a   Schiavone, Domenica ^a   Verhovez, Andrea ^a   Giraudo, Giuseppe ^a   Morello, Fulvio ^a   Veglio, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Aldosterone; Blood pressure; Brain; End organ damage

Indexed keywords

ALDOSTERONE; AMLODIPINE; ATENOLOL; CANDESARTAN; CAPTOPRIL; EPLERENONE; LOSARTAN; MINERALOCORTICOID ANTAGONIST; OXPRENOATE POTASSIUM; SPIRONOLACTONE;

BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; GYNECOMASTIA; HORMONE ACTION; HUMAN; HYPERTENSION; IMPOTENCE; MENSTRUATION DISORDER; NONHUMAN; PRIMARY HYPERALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CEREBROVASCULAR DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; RISK FACTORS; STROKE;

EID: 56549091789     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802566017     Document Type: Conference Paper

References (92)

1. Kuhlman D, Ragan C, Ferrebee JW, Atchley DW, Loeb RF. Toxic effects of deoxycorticosterone esters in dogs. Science 1939;90:496-497.
2. Webb RC, Bohr DF. What makes the pressure go up? A hypothesis. Hypertension 1981;3:160-165.
3. Gomez-Sanchez EP. What is the role of the central nervous system in mineralocorticoid hypertension? Am J Hypertens. 1991;4:374-381.
4. Gomez-Sanchez EP, Gomez-Sanchez CE. First there was one, then two . . . why more 11beta-hydroxysteroid dehydrogenases? Endocrinology. 1997;138:5087-5088.
5. MacKenzie SM, Lai M, Clark CJ, Fraser R, Gomez-Sanchez CE, Seckl JR, Connell JM, Davies E. 11beta-hydroxylase and aldosterone synthase expression in fetal rat hippocampal neurons. J Mol Endocrinol. 2002;29:319-325.
6. Ye P, Kenyon CJ, MacKenzie SM, Seckl JR, Fraser R, Connell JM, Davies E. Regulation of aldosterone synthase gene expression in the rat adrenal gland and central nervous system by sodium and angiotensin II. Endocrinology 2003;144:3321-3328.
7. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA. 1983;80:6056-6060.
8. Stewart PM, Murry BA, Mason JI. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab. 1994;79:480-484.
9. Spencer RL, Young EA, Choo PH, McEwen BS. Adrenal steroid type I and type II receptor binding: Estimates of in vivo receptor number, occupancy, and activation with varying level of steroid. Brain Res. 1990;514:37-48.
10. de Kloet ER, Van Acker SA, Sibug RM, Oitzl MS, Meijer OC, Rahmouni K, de Jong W. Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int. 2000; 57:1329-1336.
11. Roland BL, Li KX, Funder JW. Hybridization histochemical localization of 11 beta-hydroxysteroid dehydrogenase type 2 in rat brain. Endocrinology. 1995;136:4697-4700.
12. Nyakas C, De Kloet ER, Veldhuis HD, Bohus B. Hippocampal corticosterone receptors and novelty-induced behavioral activity: Effect of kainic acid lesion in the hippocampus. Brain Res. 1983;288:219-228
13. Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol. 1990;258:E649-E653.
14. Buggy J, Fink GD, Haywood JR, Johnson AK, Brody MJ. Interruption of the maintenance phase of established hypertension by ablation of the anteroventral third ventricle (AV3V) in rats. Clin Exp Hypertens. 1978-1979;1:337-353.
15. Brody MJ, Varner KJ, Vasquez EC, Lewis SJ. Central nervous system and the pathogenesis of hypertension. Sites and mechanisms. Hypertension 1991;18:III7-III12.
16. Sakai RR, Ma LY, Zhang DM, McEwen BS, Fluharty SJ. Intracerebral administration of mineralocorticoid receptor antisense oligonucleotides attenuate adrenal steroid-induced salt appetite in rats. Neuroendocrinology 1996;64:425-429.
17. Sakai RR, Ma LY, Zhang DM, McEwen BS, Fluharty SJ. Intracerebral administration of mineralocorticoid receptor antisense oligonucleotides attenuate adrenal steroid-induced salt appetite in rats. Neuroendocrinology 1996;64:425-429.
18. Kubo T, Hashimoto M. Effects of intraventricular and intraspinal 6-hydroxydopamine on blood pressure of DOCA-saline hypertensive rats. Arch Int Pharmacodyn Ther. 1979;238:50-59.
19. Reid JL, Zivin JA, Kopin IJ. Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats. Circ Res. 1975;37:569-579.
20. Betz AJ. Sodium transport from blood to brain: Inhibition by furosemide and amiloride. J Neurochem. 1983;41:1158-1164.
21. Campbell SE, Janicki JS, Matsubara BB, Weber KT. Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. Am J Hypertens. 1993;6:487-495.
22. Ritchie JM, Black JA, Waxman SG, Angelides KJ. Sodium channels in the cytoplasm of Schwann cells. Proc Natl Acad Sci USA. 1990;87:9290-9294.
23. Chassande O, Renard S, Barbry P, Lazdunski M. The human gene for diamine oxidase, an amiloride binding protein. Molecular cloning, sequencing, and characterization of the promoter. J Biol Chem. 1994;269:14484-14489.
24. Duc C, Farman N, Canessa CM, Bonvalet JP, Rossier BC. Cell-specific expression of epithelial sodium channel alpha, beta, and gamma subunits in aldosterone-responsive epithelia from the rat: Localization by in situ hybridization and immunocytochemistry. J Cell Biol. 1994; 127:1907-1921.
25. Renard S, Lingueglia E, Voilley N, Lazdunski M, Barbry P. Biochemical analysis of the membrane topology of the amiloride-sensitive Na+ channel. J Biol Chem. 1994;269:12981-12986.
26. Smith PR, Saccomani G, Joe EH, Angelides KJ, Benos DJ. Amiloride-sensitive sodium channel is linked to the cytoskeleton in renal epithelial cells. Proc Natl Acad Sci USA. 1991;88:6971-6975.
27. Marver D. Models of aldosterone action on sodium transport: emerging concepts. Adv Exp Med Biol. 1986;196:153-171.
28. Janiak PC, Lewis SJ, Brody M.J. Role of central mineralocorticoid binding sites in development of hypertension. Am J Physiol. 1990;259:R1025- R1034.
29. Gavras H, Gavras I. Salt-induced hypertension: The interactive role of vasopressin and of the sympathetic nervous system. J Hypertens. 1989;7:601-606.
30. Berecek KH. Role of central vasopressin in cardiovascular regulation. J Cardiovasc Pharmacol. 1986;8:S76-S80.
31. Wehling M, Christ M, Theisen K. Membrane receptors for aldosterone: A novel pathway for mineralocorticoid action. Am J Physiol. 1992;263:E974-E979.
32. Sakai RR, McEwen BS, Fluharty SJ, Ma LY. The amygdala: Site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int. 2000;57:1337-1345.
33. Sakai RR, Nicolaidis S, Epstein AN. Salt appetite is suppressed by interference with angiotensin II and aldosterone. Am J Physiol. 1986;251:R762-R768.
34. Osterziel KJ, Hanlein D, Willenbrock R, Eichhorn C, Luft F, Dietz R. Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure. Br Heart J. 1995; 73:517-522.
35. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes after Myocardial Infarction) Investigators. Lancet 1998;351:478-484.
36. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
37. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
38. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75-197.
39. Rahmouni K, Barthelmebs M, Grima M, Imbs JL, De Jong W. Brain mineralocorticoid receptor control of blood pressure and kidney function in normotensive rats. Hypertension 1999;33:1201-1206.
40. Rahmouni K, Barthelmebs M, Grima M, Imbs JL, De Jong W. Involvement of brain mineralocorticoid receptor in salt-enhanced hypertension in spontaneously hypertensive rats. Hypertension 2001;38:902-906.
41. Janiak PC, Lewis SJ, Brody MJ. Role of central mineralocorticoid binding sites in development of hypertension. Am J Physiol. 1990;259:R1025-R1034.
42. Gomez-Sanchez EP, Gomez-Sanchez CE. A reevaluation of the mineralocorticoid and hypertensinogenic potential of 19-hydroxyandrostenedione. Endocrinology 1986;118:2582-2587.
43. Kageyama Y, Bravo EL. Hypertensive mechanisms associated with centrally administered aldosterone in dogs. Hypertension 1988;11:750-753.
44. Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol. 1990;258:E649-E653.
45. Gomez-Sanchez EP. What is the role of the central nervous system in mineralocorticoid hypertension? Am J Hypertens. 1991;4:374-381.
46. Chander PN, Rocha R, Ranaudo J, Singh G, Zuckerman A, Stier CT Jr. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol. 2003;14:1990-1997.
47. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke prone hypertensive rats. Hypertension 1998;31:451-458.
48. Rocha R, Stier CT. Pathophysiological effects ofaldosterone in cardiovascular tissues Endocrinolol Metab. 2001;12:308-314.
49. Smeda JS, Tkachenko O. Effects of diuretics on stroke development in Kyoto-Wistar stroke-prone spontaneously hypertensive rats. Clin Sci (Lond). 1991;81:335-340.
50. Mac Leod AB, Vasdev S, Smeda JS. The role of blood pressure and aldosterone in the production of hemorrhagic stroke in captopril treated hypertensive rats. Stroke 1997;28:1821-1829.
51. Coyle P. Spatial relations of dorsal anastomoses and lesion border after middle cerebral artery occlusion. Stroke 1987;18:1133-1140.
52. Resink TJ, Scott-Burden T, Baur U, Burgin M, Buhler FR. Enhanced responsiveness to angiotensin II in vascular smooth muscle cells from spontaneously hypertensive rats is not associated with alterations in protein kinase C. Hypertension 1989;14:293-303.
53. Florian JA, Watts SW. Epidermal growth factor: A potent vasoconstrictor in experimental hypertension. Am J Physiol. 1999;276:H976-H983.
54. Dorrance AM, Osborn HL, Grekin R, Webb RC. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol. 2001;281:R944-R950.
55. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001;38:606-611.
56. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab. 2002;87:448-452.
57. White PC. Aldosterone: Direct effects on and production by the heart. J Clin Endocrinol Metab. 2003;88:2376-2383.
58. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension 2003;42:161-165.
59. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002;40:897-902.
60. Mulatero P, Stowasser M, Loh K-C, Fardella CE, Gordon R, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;83:1045-1050.
61. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997;95:1471-1478.
62. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994;121:877-885.
63. Jeck T, Weisser B, Mengden T, Erdmenger L, Grune S, Vetter W. Primary aldosteronism: Difference in clinical presentation and long-term follow-up between adenoma and bilateral hyperplasia of the adrenal glands. Clin Invest. 1994;72:979-984.
64. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
65. Sutherland DJA, Ruse JC, Laidlaw JC. Hypertension increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. J Can Med Assoc. 1966;95:1109-1119.
66. Litchfield WR, Coolidge C, Silva P, Lifton RP, Fallo F, Williams GH, Dluhy RG. Impaired potassium-stimulated aldosterone production: A possible explanation for normokalemic glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 1997;82:1507-1510.
67. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998;31:445-450.
68. Pascoe L, Jeunemaitre X, Lebrethon MC, Curnow KM, Gomez-Sanchez CE, Gasc JM, Saez JM, Corvol P. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. J Clin Invest. 1995;96:2236-2246.
69. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 1999;84:4341-4344.
70. Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev. 2002;10:97-107.
71. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992;355:262-265.
72. Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA. 1992;89:8327-8331.
73. Lifton RP, Dluhy RG, Powers M, Rich GM, Gutkin M, Fallo F, Gill JR Jr, Feld L, Ganguly A, Laidlaw JC, Murnagham DJ, Kaufman C, Ulick S, Lalouel JM. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet. 1992;2:66-74.
74. Curnow KM, Mulatero P, Emeric-Blanchouin N, Aupetit-Faisant B, Corvol P, Pascoe L. The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme. Nat Struct Biol. 1997;4:32-35.
75. Dluhy RG, Anderson B, Harlin B, Ingelfinger J, Lifton R. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr. 2001;138:715-720.
76. Wyckoff JA, Seely EW, Hurwitz S, Anderson BF, Lifton RP, Dluhy RG. Glucocorticoid-remediable aldosteronism and pregnancy. Hypertension 2000;35:668-672.
77. Mulatero P, Morra di Cella S, Williams TA, Milan A, Mengozzi G, Chiandussi L, Gomez-Sanchez CE, Veglio F. Glucocorticoid remediable aldosteronism: Low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrinol Metab. 2002;87:3187-3191.
78. Fallo F, Pilon C, Williams TA, Sonino N, Morra di Cella S, Veglio F, De Iasio R, Montanari P, Mulatero P. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. J Hum Hypertens. 2004;18:47-51.
79. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 1995;60:48-51.
80. Liddle GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 1960;20:1539-1561.
81. Mulatero P, Veglio F, Pilon C, Rabbia F, Zocchi C, Limone P, Boscaro M, Sonino N, Fallo F. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: Aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab. 1998;83:2573-2575.
82. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863-1867.
83. Mulatero P, Curnow KM, Aupetit-Faisant B, Foekling M, Gomez-Sanchez CE, Veglio F, Jeunemaitre X, Corvol P, Pascoe L. Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. J Clin Endocrinol Metab. 1998;83:3996-4001.
84. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun. 1995;207:565-571.
85. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, Corvol P, Menard J. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820-825.
86. DeGasparo M. Antialdosterones: Incidence and prevention of sexual side effects. J Ster Biochem. 1989;32:223-227.
87. Hoyert DL, Kochanek KD, Murphy SL. Deaths: Final data for 1997. Natl Vital Stat Rep. 1999;47:1-104.
88. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-1026.
89. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
90. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
91. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288: 2981-2997.
92. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.